Truly grateful for the opportunity. Sincere thank you to all my collaborators, patients and everyone who believes in growing science for better patient outcomes. #betterscience R&D at UHCW UHCWNeurology UHCW NHS Trust Warwick CTU

Pleased to share our latest paper hot off the press ⁦Journal of Neurology, Neurosurgery and Psychiatry⁩ on optimal therapy at MOGAD onset and the influence on delaying relapses with ⁦Dr Benjamin P Trewin⁩ Tomas Kalincik ⁦@RussellCDale⁩ ⁦Fabienne Brilot⁩ ⁦Sydney Health⁩ jnnp.bmj.com/content/early/…

✨UHCW has become the first trust in England to deliver a revolutionary new Parkinson's treatment to an outpatient. Seamus Connolly, who was diagnosed in 2013, underwent his treatment at University Hospital Coventry. 🔗Read the full story: uhcw.nhs.uk/news/uhcw-beco…

Today is #InternationalClinicalTrialsDay - so what better time to take a look at the clinical trials taking us closer to stopping MS This video shows Neurologist Dr Tarunya Arun, Research Nurse Kelly Westwood, and trial participant Tony Watch the video: mssoc.uk/3V7jNjS

An opportunity for female MS patients to get involved in research. If you fit the criteria below then do drop a line to [email protected] Please share. Cheers. Multiple Sclerosis Neurologist dr Agne Straukiene Wonky McParkinson's fox/vixen Klaus Schmierer🇺🇦 Tarunya arun Wendy Joberns Centre for Preventive Neurology Trishna Bharadia BA(hons), MFPM(hon) Mark Webb

Treatment continuation at year 5 with Cladribine, efficacy and safety, pleased to have contributed with the first reviews on this topic. Our latest paper is now out. R&D at UHCW michelle meehan UHCWNeurology pubmed.ncbi.nlm.nih.gov/39180839/

Key step towards early diagnosis and treatment of MS

Misdiagnosis rates in MS~15%, upto 1 in 20. Lack of expertise surrounding diagnostic criteria is one of the key issues. Health care professional education important. #ECTRIMS2024 #global perspective

Jiwon Oh (US): tolebrutinib vs teriflunimode in RRMS (GEMINI trials). - ARR : no difference! - 6m CDW: 29% reduction on tolebr - 3m CDW: 27% reduction on tolebr - New Gd+ lesions are higher on tolebrutinib! - T2 lesions: no difference - good safety profile #ECTRIMS2024

And our amazing Neurology Research Team are pictured in the Quality Account! So #UHCWProud 💙

We are appointing a consultant neurologist with specialist interest in MS and neuroinflammation to join our vibrant and expanding team at Coventry. Come and join us! Job advert now out on NHS jobs. If interested I would love to hear from you. DM me. UHCWNeurology UHCW NHS Trust

Thank you Tarunya arun for hosting the Midlands Neurological Society Meeting 2024. Delighted to share how OPM-MEG will transform neurology, and very grateful to receive the Research Prize! **Functional imaging + structural imaging = more complete picture of brain health**

Among my last posts as I move to Bluesky

Great to see this out. We need to build the next generation of specialists robustly and now. Need to invest in our trainees urgently. msard-journal.com/article/S2211-… Ruth Dobson Klaus Schmierer🎗️🇺🇦 Helen Ford Neurology Trainees Dr Niall MacDougall

ABN SIG trainee day underway. Great to see so many trainees, keen to learn and network. Neurology Trainees

Here is the programme for our 2025 Sarcoidosis Patient Day, taking place on the 29th April! 📣 There will be lots of time dedicated to answering your questions, so even if you can't make it for the full event be sure to drop in when you can! Sign up here: store.sarcoidosisuk.org/product/sarcoi…

#Cladribine tablets coming of age: expert views on the impact of the new label for patients with #MS and the #NHS. Read the article here: acnr.co.uk/articles/cladr… and discuss it with Professor of Neurology, Klaus Schmierer in our online forum: forums.acnr.co.uk/welcome #CladT

Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria - The Lancet Neurology thelancet.com/journals/laneu…

In women with multiple sclerosis, disease-modifying therapy management during pregnancy increased relapse risk, particularly in patients receiving natalizumab with prolonged interruption or fingolimod. ja.ma/4nfdgP5